Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders Biocytogen Pharmaceuticals a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, announced a strategic collaboration with…
ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer and Expands Leadership Team to Drive Clinical Adoption of Early Cancer Detection Tests ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced…
iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment…
Flowserve Appoints Brian Savoy to Board of Directors Flowserve Corporation, a global leader in flow control products and services for infrastructure markets, has announced the appointment of Brian Savoy to its Board of Directors. His appointment became effective on March…
AOM Infusion Joins Limited Distribution Network for QIVIGY® Immune Globulin Therapy AOM Infusion, a leading specialty infusion pharmacy and care provider in the United States, has announced that it has been selected to join the limited distribution network for QIVIGY,…
TIXiMED Expands Program-Related Investment from the Helmsley Charitable Trust to Advance T1D Therapy Development TIXiMED, Inc., a clinical-stage pharmaceutical company focused on developing innovative therapies for diabetes, has announced an expansion of its program-related investment (PRI) from The Leona M.…
Meiji Seika Pharma Co., Ltd. has announced the initiation of a Phase I clinical trial for ME3241, an innovative anti-PD-1 agonist monoclonal antibody developed through a research collaboration with the Foundation for Biomedical Research and Innovation at Kobe (FBRI). The…
EcoOnline Launches Inaugural Mega Trends Report Highlighting 2025 Shift from Compliance to Connected Ris EcoOnline, a leading global provider of safety and sustainability software, today unveiled its first-ever EcoOnline Mega Trends Report, the result of 18 months of in-depth primary…
Orbia Releases 2025 Impact Report Highlighting Sustainability and Long-Term Growth Orbia Advance Corporation, S.A.B. de C.V. has published its 17th annual impact report, outlining the company’s performance in 2025 and the strategic actions taken to strengthen resilience, sustainability and long-term…
Acacia Research Reports Strong Fourth Quarter and Record Full-Year 2025 Results Acacia Research Corporation a company that acquires and operates businesses across the industrial, energy, and technology sectors, has announced its financial results for the fourth quarter and the full…
Cintas to Acquire UniFirst in $5.5 Billion Deal to Expand Services and Innovation Cintas Corporation has announced a definitive agreement to acquire UniFirst Corporation in a transaction valued at approximately $5.5 billion. The deal will combine two well-known family-founded companies…